乳腺癌放射性心脏损伤及其预防措施的研究进展

doi:10.11904/j.issn.1002-3070.2023.06.010

摘要/Abstract

摘要： 放疗是降低乳腺癌局部复发率和死亡率的有效手段,然而,放射性心脏损伤的远期副作用风险不容忽视。特别是左乳放疗的患者,由于心脏在放疗射野内,其心脏损伤的风险更高,进而增加放射性心脏病的发生,最终影响远期生存率和生活质量。因此预防放射性心脏损伤尤为重要,主要措施包括使用先进的放疗技术,如调强放疗、容积调强弧形放疗、深吸气屏气下放疗、俯卧位放疗、质子束放疗等,或者优化心脏亚结构的放疗计划,进而降低心脏关键结构的照射剂量。本文将分别对乳腺癌放射性心脏损伤的病理生理机制、临床表现、危险因素、预防措施的研究进展进行综述。

关键词: 乳腺癌, 放射治疗, 心脏损伤, 心脏亚结构剂量, 预防措施

Abstract: Radiotherapy is an effective way to reduce the local recurrence rate and mortality of breast cancer.However,the risk of long-term side effects of radiation-induced cardiac injury cannot be ignored.Especially for patients undergoing left breast radiation therapy,the risk of cardiac injury is higher due to the heart being within the radiation field,which increases the incidence of radiation induced heart disease and ultimately affects long-term survival rate and quality of life.Therefore,it is particularly important to prevent radiation induced cardiac injury.The main measures include using advanced radiation therapy techniques such as intensity modulated radiation therapy,volume modulated arc radiotherapy,deep inhalation and breath holding radiation therapy,prone position radiation therapy,proton beam therapy,etc.or optimizing the radiotherapy plan for cardiac substructure to reduce the radiation dose to key cardiac structures.This article will review the research progress of pathophysiological mechanism,clinical manifestations,risk factors and preventive measures of radiation-induced cardiac injury in breast cancer.

Key words: Breast cancer, Radiotherapy, Heart injuries, Cardiac substructure dose, Preventive measures

中图分类号:

R737.9

冯楚然, 曹剑钊, 陈子印, 张大昕, 鲁海玲. 乳腺癌放射性心脏损伤及其预防措施的研究进展[J]. 实用肿瘤学杂志, 2023, 37(6): 513-518.

FENG Churan, CAO Jianzhao, CHEN Ziyin, ZHANG Daxin, LU Hailing. Research progress on radiation-induced cardiac injury in breast cancer and its preventive measures[J]. Journal of Practical Oncology, 2023, 37(6): 513-518.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/10.11904/j.issn.1002-3070.2023.06.010

http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/Y2023/V37/I6/513

参考文献

1 Sung H,Ferlay J,Siegel RL,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2021,71(3):209-249.
2 Taylor C,Dodwell D,McGale P,et al.Radiotherapy to regional nodes in early breast cancer:an individual patient data meta-analysis of 14 324 women in 16 trials[J].Lancet,2023,402(10416):1991-2003.
3 Rygiel K.Cardiotoxic effects of radiotherapy and strategies to reduce them in patients with breast cancer:an overview[J].Cancer Res Ther.2017,13(2):186-192.
4 Harris EER.Breast radiation and the heart:cardiac toxicity and cardiac avoidance[J].Clin Breast Cancer,2021,21(6):492-496.
5 Bikiewicz A,Banach M,von Haehling S.Adjuvant breast cancer treatments cardiotoxicity and modern methods of detection and prevention of cardiac complications[J].ESC Heart Fail,2021,8(4):2397-2418.
6 Darby SC,Ewertz M,McGale P,et al.Risk of ischemic heart disease in women after radiotherapy for breast cancer[J].N Engl J Med,2013,368(11):987-998.
7 van den Bogaard VAB,Ta BDP,van der Schaaf A,et al.Validation and modification of a prediction model for acute cardiac events in patients with breast cancer treated with radiotherapy based on three-dimensional dose distributions to cardiac substructures[J].J Clin Oncol,2017,35(11):1171-1178.
8 Wennstig AK,Garmo H,Wadsten L,et al.Risk of coronary stenosis after adjuvant radiotherapy for breast cancer[J].Strahlenther Onkol,2022,198(7):630-638.
9 Paulus WJ,Tschöpe C.A novel paradigm for heart failure with preserved ejection fraction:comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation[J].J Am Coll Cardiol,2013,62(4):263-271.
10 Mehta LS,Watson KE,Barac A,et al.Cardiovascular disease and breast cancer:where these entities intersect:a scientific statement from the American Heart Association[J].Circulation,2018,137(8):e30-e66.
11 Zhang Z,Lu M,Chen C,et al.Holo-lactoferrin:the link between ferroptosis and radiotherapy in triple-negative breast cancer[J].Theranostics.2021,11(7):3167-3182.
12 Huang RX,Zhou PK.DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer[J].Signal Transduct Target Ther,2020,5(1):60.
13 Habraken Y,Piette J.NF-κB activation by double-strand breaks[J].Biochemical pharmacology,2006,72(9):1132-1141.
14 Kura B,Babal P,Slezak J.Implication of microRNAs in the development and potential treatment of radiation-induced heart disease[J].Can J Physiol Pharmacol,2017,95(10):1236-1244.
15 Jaworski C,Mariani JA,Wheeler G,et al.Cardiac complications of thoracic irradiation[J].J Am Coll Cardiol,2013,61(23):2319-2328.
16 Curigliano G,Lenihan D,Fradley M,et al.Management of cardiac disease in cancer patients throughout oncological treatment:ESMO consensus recommendations[J].Ann Oncol,2020,31(2):171-190.
17 Desai MY,Windecker S,Lancellotti P,et al.Prevention,diagnosis,and management of radiation-associated cardiac disease:JACC scientific expert panel[J].J Am Coll Cardiol,2019,74(7):905-927.
18 Ponikowski P,Voors AA,Anker SD,et al.2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure:The task force for the diagnosis and treatment of acute and chronic heart failure of the european society of cardiology(esc)developed with the special contribution of the Heart Failure Association(HFA)of the ESC[J].Eur J Heart Fail,2016,18(8):891-975.
19 Marinko T.Pericardial disease after breast cancer radiotherapy[J].Radiology and Oncology,2018,53(1):1-5.
20 Coma N,Resta H,Moral S,et al.Uncommon short-and long-term cardiological side effects of thoracic radiation:a report of two cases[J].Future Cardiol,2023,19(11):529-535.
21 Errahmani MY,Locquet M,Spoor D,et al.Association between cardiac radiation exposure and the risk of arrhythmia in breast cancer patients treated with radiotherapy:a case-control study[J].Front Oncol,2022,12:892882.
22 Errahmani MY,Thariat J,Ferrieres J,et al.Risk of pacemaker implantation after radiotherapy for breast cancer:a study based on French nationwide health care database sample[J].Int J Cardiol Heart Vasc,2021,38:100936.
23 Nabiałek-Trojanowska I,Lewicka E,Wrona A,et al.Cardiovascular complications after radiotherapy[J].Cardiol J,2020,27(6):836-847.
24 Meattini I,Poortmans PM,Aznar MC,et al.Association of breast cancer irradiation with cardiac toxic effects:a narrative review[J].JAMA Oncol,2021,7(6):924-932.
25 Łukasiewicz S,Czeczelewski M,Forma A,et al.Breast cancer—epidemiology,risk factors,classification,prognostic markers,and current treatment strategies—an updated review[J].Cancers,2021,13(17):4287.
26 Taylor C,Correa C,Duane FK,et al.Estimating the risks of breast cancer radiotherapy:evidence from modern radiation doses to the lungs and heart and from previous randomized trials[J].J Clin Oncol,2017,35(15):1641-1649.
27 Jain D,Russell RR,Schwartz RG,et al.Cardiac complications of cancer therapy:pathophysiology,identification,prevention,treatment,and future directions[J].Curr Cardiol Rep,2017,19(5):36.
28 Haussmann J,Budach W,Nestle-Krämling C,et al.Predictive factors of long-term survival after neoadjuvant radiotherapy and chemotherapy in high-risk breast cancer[J].Cancers,2022,14(16):4031.
29 Tocchetti CG,Cadeddu C,Di Lisi D,et al.From molecular mechanisms to clinical management of antineoplastic drug-induced cardiovascular toxicity:a translational overview[J].Antioxid Redox Signal,2019,30(18):2110-2153.
30 Yang H,Bhoo-Pathy N,Brand JS,et al.Risk of heart disease following treatment for breast cancer–results from a population-based cohort study[J].Elife,2022,11:e71562.
31 Yang B,Wei XD,Zhao YT,et al.Dosimetric evaluation of integrated IMRT treatment of the chest wall and supraclavicular region for breast cancer after modified radical mastectomy[J].Med Dosim,2014,39(2):185-189.
32 Wang R,Shen J,Yan H,et al.Dosimetric comparison between intensity-modulated radiotherapy and volumetric-modulated arc therapy in patients of left-sided breast cancer treated with modified radical mastectomy:CONSORT[J].Medicine,2022,101(2):e28427.
33 Frengen J,Vikstrom J,Mjaaland I,et al.Locoregional breast radiotherapy including IMN:optimizing the dose distribution using an automated non-coplanar VMAT-technique[J].2023,62(10):1169-1177.
34 Bergom C,Currey A,Desai N,et al.Deep inspiration breath hold:techniques and advantages for cardiac sparing during breast cancer irradiation[J].Front Oncol,2018,8:87.
35 Simonetto C,Eidemüller M,Gaasch A,et al.Does deep inspiration breath-hold prolong life? Individual risk estimates of ischaemic heart disease after breast cancer radiotherapy[J].Radiother Oncol,2019,131:202-207.
36 Eber J,Schmitt M,Dehaynin N,et al.Evaluation of cardiac substructures exposure of DIBH-3DCRT,FB-HT,and FB-3DCRT in hypofractionated radiotherapy for left-sided breast cancer after breast-conserving surgery:an in silico planning study[J].Cancers,2023,15(13):3406.
37 Lai J,Zhong F,Deng J,et al.Prone position versus supine position in postoperative radiotherapy for breast cancer:A meta-analysis[J].Medicine,2021,100(20):e26000.
38 Formenti SC,Dewyngaert JK,Jozsef G,et al.Prone vs supine positioning for breast cancer radiotherapy[J].Jama,2012,308(9):861-863.
39 Gaál S,Kahán Z,Paczona V,et al.Deep-inspirational breath-hold(DIBH)technique in left-sided breast cancer:various aspects of clinical utility[J].Radiat Oncol,2021,16(1):89.
40 Shumway DA,Atkins KM.Prone whole-breast radiotherapy—better than supine?[J].Jama Oncol,2022,8(7):983-985.
41 Mast ME,Vredeveld EJ,et al.Whole breast proton irradiation for maximal reduction of heart dose in breast cancer patients[J].Breast Cancer Res Treat,2014,148(1):33-39.
42 Loap P,Goudjil F,Servois V,et al.Radiation exposure of cardiac conduction nodes during breast proton therapy[J].Int J Part Ther,2023,10(1):59-64.
43 Boersma LJ,Sattler MGA,Maduro JH,et al.Model-based selection for proton therapy in breast cancer:development of the national indication protocol for proton therapy and first clinical experiences[J].Clin Oncol,2022,34(4):247-257.
44 Momin S,Lei Y,McCall NS,et al.Mutual enhancing learning-based automatic segmentation of CT cardiac substructure[J].Phys Med Biol,2022,67(10):105008.
45 Milo MLH,Nyeng TB,Lorenzen EL,et al.Atlas-based auto-segmentation for delineating the heart and cardiac substructures in breast cancer radiation therapy[J].Acta Oncol,2022,61(2):247-254.
46 Piroth MD,Baumann R,Budach W,et al.Heart toxicity from breast cancer radiotherapy:current findings,assessment,and prevention[J].Strahlenther Onkol,2019,195(1):1-12.

[1]	鲁泓男, 夏冰舒, 乔坤, 张世园, 黄元夕, 鲁祥石. GAS1与乳腺癌免疫治疗及药物敏感性的关系[J]. 实用肿瘤学杂志, 2023, 37(4): 351-359.
[2]	陈飞, 王颖, 曾传琴. B7-H4在乳腺癌组织中的表达及其与患者新辅助化疗后腋窝淋巴结转移的相关性分析[J]. 实用肿瘤学杂志, 2023, 37(4): 360-366.
[3]	李福程, 贾斯媛, 巴玉玲, 罗丹利, 肖敏. 免疫检查点抑制剂在早期乳腺癌新辅助治疗中的研究进展[J]. 实用肿瘤学杂志, 2023, 37(4): 367-371.
[4]	马艳玲, 钱立庭, 魏东华, 尹惠萍, 张娟, 张小鹏. 2014—2017年安徽省合肥市城市乳腺癌高危人群筛查率及其影响因素分析[J]. 实用肿瘤学杂志, 2023, 37(3): 200-206.
[5]	隋世尧, 郑玮, 杨子涵, 庞达. lncRNA SNHG4通过EP300-SNHG4-GPX4轴抑制乳腺癌细胞铁死亡[J]. 实用肿瘤学杂志, 2023, 37(3): 215-223.
[6]	张庆怀, 韩阿蒙, 杨森, 李秀梅, 赵健鑫, 张彦秋. 乳腺癌患者保乳术后五种放疗技术的疗效比较研究[J]. 实用肿瘤学杂志, 2023, 37(3): 224-229.
[7]	杨帅, 王新恒, 吴佳乐, 付子彤, 魏博, 杨灵冰, 许守平. 单细胞测序技术在乳腺癌中的研究进展[J]. 实用肿瘤学杂志, 2023, 37(3): 287-292.
[8]	张馨, 吴羡美, 李虹, 刘晓舟, 孔德文, 陈琢. 1990—2019年中国女性人群归因于代谢危险因素的乳腺癌疾病负担[J]. 实用肿瘤学杂志, 2023, 37(2): 107-111.
[9]	刘欣欣, 马西元, 缪美琪, 王语晴, 陈晶. IL-6及其受体在乳腺癌治疗中的作用研究进展[J]. 实用肿瘤学杂志, 2023, 37(2): 149-154.
[10]	冯诚天, 黄芙蓉, 姜永冬. 脂质代谢与乳腺癌曲妥珠单抗耐药性机制的相关性研究[J]. 实用肿瘤学杂志, 2023, 37(2): 155-159.
[11]	文世超, 王静萱. 铜依赖性细胞死亡及铜在乳腺癌治疗中的研究现状[J]. 实用肿瘤学杂志, 2023, 37(2): 185-189.
[12]	余银平, 蔺嘉楠, 王立中, 蒋威华. 癌源性外泌体对乳腺癌MCF-7细胞生物学行为的影响[J]. 实用肿瘤学杂志, 2023, 37(1): 26-31.
[13]	教冲, 史雨鑫, 徐浩译, 马斌林, 董朝. 二甲双胍对不同亚型乳腺癌伴2型糖尿病患者预后影响的研究[J]. 实用肿瘤学杂志, 2022, 36(6): 531-537.
[14]	吴蕊玥, 朱凯丽, 杨景茹, 令晓玲. HER2低表达乳腺癌的临床研究进展[J]. 实用肿瘤学杂志, 2022, 36(6): 570-575.
[15]	王星涵, 吕雅蕾. 曲妥珠单抗耐药机制及HER2阳性乳腺癌耐药后的治疗策略[J]. 实用肿瘤学杂志, 2022, 36(5): 445-451.